An open-label study to asses the rate of failure of an Enbrel (etanercept) SureClick auto-injector in subjects with rheumatoid arthritis

Trial Profile

An open-label study to asses the rate of failure of an Enbrel (etanercept) SureClick auto-injector in subjects with rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2009

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 19 Feb 2009 Trial location (USA) added as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Actual end date (Jul 06) added as reported by ClinicalTrials.gov.
    • 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top